Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea

References

• Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients’ lives. Clin Exp Rheumatol. 2010;28(3 Suppl 59):S32–S40.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Meissner B, Trivedi D, You M, et al. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ. 2014;17(4):259–265.
   PubMedGoogle Scholar
• Lee MY, Shin JY, Park SY, et al. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: an analysis of the South Korean National Health Insurance Database. Semin Arthritis Rheum. 2018;47(4):485–491.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
   PubMed Web of Science ®Google Scholar
• The Ministry of Health and Welfare, Republic of Korea. Revised ‘Details for evaluation criteria and procedures for reimbursement’ notification No. 2013-183. 2013.
   Google Scholar
• Wilke T, Mueller S, Lee SC, et al. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. BMC Musculoskelet Disord. 2017;18(1):332.
   PubMedGoogle Scholar
• Jones G, Hall S, Bird P, et al. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. Int J Rheum Dis. 2018;21(8):1581–1590.
   PubMed Web of Science ®Google Scholar
• Dalén J, Svedbom A, Black CM, et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016;36(7):987–995.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Brocq O, Perdriger A, et al. Non–TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172–1180.
   PubMed Web of Science ®Google Scholar
• Calip GS, Adimadhyam S, Xing S, et al. Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. Semin Arthritis Rheum. 2017;47(2):157–164.
   PubMed Web of Science ®Google Scholar
• Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan. 2008;24(1):63–71.
   PubMed Web of Science ®Google Scholar
• Hwang SH, Han S, Choi H, et al. Trends in the prescription of benzodiazepines for the elderly in Korea. BMC Psychiatry. 2017;17(1):303.
   PubMedGoogle Scholar
• Jung HK, Kim YH, Park JY, et al. Estimating the burden of irritable bowel syndrome: analysis of a nationwide Korean database. J Neurogastroenterol Motil. 2014;20(2):242–252.
   PubMed Web of Science ®Google Scholar
• Cho SK, Sung YK, Choi CB, et al. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database. Rheumatol Int. 2013;33(12):2985–2992.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Sruamsiri R. Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. PPA. 2016;10:1509–1519.
   Google Scholar
• Neubauer S, Cifaldi M, Mittendorf T, et al. Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Econ Rev. 2014;4(1):32.
   PubMedGoogle Scholar
• Chastek B, Chen C-I, Proudfoot C, et al. Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA. Adv Ther. 2017;34(11):2422–2435.
   PubMed Web of Science ®Google Scholar
• Kaine JL. Abatacept for the treatment of rheumatoid arthritis: a review. Curr Ther Res Clin Exp. 2007;68(6):379–399.
   PubMed Web of Science ®Google Scholar
• Choquette D, Bessette L, Alemao E, et al. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata clinical database and registry. Arthritis Res Ther. 2019;21(1):138.
   PubMedGoogle Scholar
• Kaufmann J, Feist E, Roske AE, et al. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol. 2013;32(9):1347–1355.
   PubMed Web of Science ®Google Scholar
• Kim H-L, Lee M-Y, Park S-Y, et al. Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach. Arch Pharm Res. 2014;37(5):662–670.
   PubMed Web of Science ®Google Scholar
• Johnston SS, McMorrow D, Farr AM, et al. Comparison of biologic disease-modifying antirheumatic drug therapy persistence between biologics among rheumatoid arthritis patients switching from another biologic. Rheumatol Ther. 2015;2(1):59–71.
   PubMed Web of Science ®Google Scholar
• Dos Santos JBR, Guerra Junior AA, da Silva MRR, et al. First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Rev Clin Pharmacol. 2019;12(4):363–370.
   PubMed Web of Science ®Google Scholar
• Ebina K, Hashimoto M, Yamamoto W, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis – the ANSWER cohort study. PLOS One. 2018;13(3):e0194130.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Hansen RA, Rao JK, et al. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. Ann Pharmacother. 2012;46(11):1491–1505.
   PubMed Web of Science ®Google Scholar
• Aaltonen KJ, Joensuu JT, Pirilä L, et al. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol. 2017;46(5):359–363.
   PubMed Web of Science ®Google Scholar
• Boone NW, Sepriano A, van der Kuy P-H, et al. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time. RMD Open. 2019;5(1):e000836.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Symmons DPM, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(6):1786–1794.
   PubMed Web of Science ®Google Scholar
• Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016;353:i1777.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32.
   PubMed Web of Science ®Google Scholar
• Tang B, Rahman M, Waters HC, et al. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30(7):1375–1384.
   PubMed Web of Science ®Google Scholar
• Fisher A, Bassett K, Wright JM, et al. Comparative persistence of the TNF antagonists in rheumatoid arthritis – a population-based cohort study. PLoS One. 2014;9(8):e105193.
   PubMed Web of Science ®Google Scholar
• Lauper K, Mongin D, Iannone F, et al. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open. 2018;4(2):e000809.
   PubMed Web of Science ®Google Scholar
• Park J, Lee M, Nam JH, et al. PMS75: treatment patterns and healthcare resource use of rheumatoid arthritis patients treated with biologic disease-modifying anti-rheumatic drugs in South Korea: results from the HIRA health insurance claims database. Value Health. 2017;20(5):A154.
   Web of Science ®Google Scholar